Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04543188 · ClinicalTrials.gov registry record · Phase 1
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT04543188 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 65 participants.
The verdict
NCT04543188, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated advanced solid tumor malignancies with and without brain involvement.
Interventions
- DRUG Midazolam
- DRUG Binimetinib
- DRUG PF-07284890
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2021-01-08 |
| Est. Completion | 2024-03-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04543188
The ClinicalTrials.gov registry entry for NCT04543188 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Midazolam is the first listed.
NCT04543188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04543188 about?
NCT04543188 is a clinical study titled "A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement". First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated advanced solid tumor malignancies with and without brain involvement.
What is the current status of trial NCT04543188?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2021-01-08. Estimated completion is 2024-03-20.
What interventions are being tested in trial NCT04543188?
The interventions under investigation include: Midazolam (DRUG), Binimetinib (DRUG), PF-07284890 (DRUG).
Who is sponsoring clinical trial NCT04543188?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.